Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal …

…, Z Erjavec, AME van der Torren, JJM Van der Hoeven… - 2013 - ascopubs.org
3502 Background: The optimal duration of chemotherapy and bevacizumab in mCRC is not
well established. The CAIRO3 study investigated the efficacy of maintenance treatment with …

Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models

…, JHCJM de Haes, JJM van der Hoeven… - Journal of Clinical …, 2014 - ascopubs.org
Background It is a challenge for oncologists to distinguish patients with breast cancer who
can forego adjuvant systemic treatment without negatively affecting survival from those who …

[HTML][HTML] Effects of short-term fasting on cancer treatment

S de Groot, H Pijl, JJM van der Hoeven… - Journal of Experimental & …, 2019 - Springer
Growing preclinical evidence shows that short-term fasting (STF) protects from toxicity while
enhancing the efficacy of a variety of chemotherapeutic agents in the treatment of various …

Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography

R Bos, JJM Van der Hoeven, E Van der Wall… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: Variable uptake of the glucose analog 18 fluorodeoxyglucose (FDG) has been
noticed in positron emission tomography (PET) studies of breast cancer patients, with low …

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal …

…, J Tol, HJJ Braun, P Nieboer, JJM van der Hoeven… - The Lancet, 2015 - thelancet.com
Background The optimum duration of first-line treatment with chemotherapy in combination
with bevacizumab in patients with metastatic colorectal cancer is unknown. The CAIRO3 …

[HTML][HTML] Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

…, MD Carpentier, H Putter, JJM van der Hoeven… - Nature …, 2020 - nature.com
Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while
enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/…

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

…, D van Beek, E de Bruijn, JJM van der Hoeven… - Nature …, 2023 - nature.com
Two decades after the genomics revolution, oncology is rapidly transforming into a genome-driven
discipline, yet routine cancer diagnostics is still mainly microscopy based, except for …

[HTML][HTML] The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

…, D Houtsma, H Putter, JJM van der Hoeven… - BMC cancer, 2015 - Springer
Background Preclinical evidence shows that short-term fasting (STF) protects healthy cells
against side effects of chemotherapy and makes cancer cells more vulnerable to it. This pilot …

[PDF][PDF] Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary

…, HH Helgason, J Wesseling, JJ Van der Hoeven… - J Clin Oncol, 2008 - academia.edu
… Helgason, Jelle Wesseling, Jacobus JM van der Hoeven, Marc … Helgason, Jelle Wesseling,
Jacobus JM van der Hoeven, Arno … Helgason, Jelle Wesseling, Jacobus JM van der Hoeven, …

Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1–treated patients in the Dutch Melanoma Treatment Registry

…, MJ Boers-Sonderen, JJM van der Hoeven… - Clinical Cancer …, 2020 - AACR
Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause
severe immune-related toxicity necessitating immunosuppressive treatment. Whether …